<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88978">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01833052</url>
  </required_header>
  <id_info>
    <org_study_id>HZL-01-TAVI</org_study_id>
    <nct_id>NCT01833052</nct_id>
  </id_info>
  <brief_title>CLaret Embolic Protection ANd TAVI - Trial</brief_title>
  <acronym>CLEAN-TAVI</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized study was designed to investigate the benefit of using a
      Filter-Protection-Device (Claret MontageTM Dual Filter System) during transcatheter aortic
      valve implantation (TAVI) with a Medtronic CoreValve®.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Rate and Size of Cerebral Embolism</measure>
    <time_frame>2 days after Intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary endpoint ist the rate and the size of cerebral embolism in postinterventional Magnetic Resonance Imaging (MRI).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Frequency of Cerebral Perfusion Defects After TAVI</condition>
  <condition>Size of Cerebral Perfusion Defects After TAVI</condition>
  <arm_group>
    <arm_group_label>Cerebral Protection Filter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient is treated with Cerebral protection Filter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Cerebral Protection Filter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient is not treated with Cerebral protection Filter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAVI (Medtronic CoreValve)</intervention_name>
    <arm_group_label>Cerebral Protection Filter</arm_group_label>
    <arm_group_label>No Cerebral Protection Filter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Claret-Filter</intervention_name>
    <arm_group_label>Cerebral Protection Filter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be scheduled to undergo an endovascular aortic valve prosthesis
             (Medtronic CoreValve®) implant procedure with the femoral artery as the intended
             access site for the valve delivery system.

        Exclusion Criteria:

          -  Patient is unsuitable for TAVI

          -  Prior Stroke or TIA in the last 12 month

          -  Carotic stenosis &gt;70%

          -  Relevant stenosis of the brachiocephalic trunc or the right subclavian artery

          -  Expected Non-compliance for follow-ups

          -  Pregnancy

          -  Patient is already recruited for another study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Leipzig Herzzentrum</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Linke, Prof. Dr. med.</last_name>
      <phone>0049 341 865 25 2016</phone>
      <email>linkea@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephan Haussig, Dr. med.</last_name>
      <phone>0049 341 865 252515</phone>
      <email>hast@med.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 15, 2013</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. A. Linke</investigator_full_name>
    <investigator_title>Prof. Dr. med. A. Linke</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
